Replay

📍 San Diego, United States🗓 Founded 2021👥 33 employees💰 Last funded 2023
Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA. The Company has assembled a toolkit of disruptive platform technologies – including a high payload capacity HSV platform, a hypoimmunogenic platform, and a genome writing platform – to address the scientific challenges currently limiting clinical progress and preventing genomic medicine from realising its full potential. The Company’s hub-and-spoke business model separates technology development within Replay from therapeutic development in product companies, which leverage the technology platforms. For example, Replay’s synHSV™ technology, a high payload capacity HSV vector capable of delivering up to 30 times the payload of AAV, is utilized by Replay’s four gene therapy product companies, bringing big DNA treatments to diseases affecting the skin, eye, brain, and muscle. The Company has, additionally, established an enzyme writing product company engaging its evolutionary inference machine learning and genome writing technology to optimize functionality. Replay is led by a world-class team of academics, entrepreneurs and industry experts.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2021
Founded
Investor geography2 countries
Singapore
2
United States
1
Investor activity2022–2023 · investors recorded per year
2022120232
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Replay?
Replay has 3 investors on record on gritt.io, including 3 early-stage backers.
When did Replay last raise funding?
The most recent investment in Replay recorded on gritt.io was in 2023.
When was Replay founded?
Replay was founded in 2021.
What industry is Replay in?
Replay operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Replay based?
Replay is headquartered in San Diego, United States.